Group 3 innate lymphoid cells (ILC3s) are tissue-resident innate lymphocytes functionally resembling T H 17/22 cells in the adaptive arm of the immune system. However, innate lymphoid cells (ILCs) lack rearranged antigen-specific receptors. In human subjects expression of the natural cytotoxicity receptor 44 (NKp44) distinguishes 2 subsets of ILC3s: IL-17-producing NKp44 2 and IL-22-producing NKp44 1 ILC3s. 1, 2 The human healthy intestine is dominated by the IL-22-expressing NKp44 1 ILC3s, 3, 4 whereas IL-17-and IFN-g-producing NKp44
2 ILC3s and group 1 innate lymphoid cells accumulate in the inflamed gut. 3, 4 Several mouse studies demonstrated the protective role of ILC3-derived IL-22 during intestinal homeostasis and inflammation. [5] [6] [7] [8] However, it is increasingly recognized that dysregulated ILC3 responses can promote intestinal inflammation 9, 10 and inflammation-induced tumorigenesis. [11] [12] [13] [14] According to mouse studies, IL-17 and IFN-g crucially contribute to the IL-23-dependent innate colitis. 15 However, therapeutic targeting of IL-17 (secukinumab) and IFN-g (fontolizumab) in patients with inflammatory bowel disease (IBD) did not provide clear beneficial effects. 16, 17 In fact, anti-IL-17 treatment worsened inflammation. 16 IL-23 is the major driver of human and mouse ILC3 cytokine production, similarly to T H 17/22 cells. 5, [18] [19] [20] IL-23 acts on the IL-23 receptor (IL-23R) and induces recruitment of retinoic acid receptor-related orphan receptor gt (RORgt) and aryl hydrocarbon receptor (AhR) to the promoter of ILC3-specific cytokines. 21, 22 IL-1b can work in synergy with IL-23 through activating the type I IL-1 receptor (IL-1R1)/myeloid differentiation response gene-88 (MyD88) pathway. 23, 24 In contrast to anti-IL-17 therapy, initial therapeutic targeting of IL-23/IL-12 (ustekinumab) appears to be very efficient for patients with Crohn disease (CD) unresponsive to anti-TNF treatment. [25] [26] [27] Therefore we turned our attention to potential inhibitors of the IL-23R pathway in ILC3s because they would constitute interesting therapeutic agents in patients with IBD.
Recently, it was shown that vitamin D receptor (VDR)-deficient mice display increased intestinal accumulation of IL-22-expressing ILCs with accompanying dysbiosis, 28 suggesting that vitamin D-VDR signaling might be a negative modulator of ILC3 function. Vitamin D deficiency has been reported as a risk factor for IBD and colorectal cancer in observational studies. [29] [30] [31] [32] Similarly, VDR-deficient mice are more susceptible to colitis and have more severe disease. [33] [34] [35] Vitamin D is a crucial immunomodulator acting through VDR, an intranuclear receptor and transcription factor. Several inflammatory cytokines, such as IL-1, IL-6, IL-8, and IL-17, can be positively or negatively regulated by vitamin D, depending on the context and activation status of the immune cells. 36 Notably, vitamin D reduces T H 17-specific cytokine production, [37] [38] [39] and thus it emerges as a potential regulator of ILC3s.
Here we determined how the active form of vitamin D, 1a,25-dihydroxy vitamin D3 (1,25D) , modulates the function of IL-23 plus IL-1b-activated human tonsillar and intestinal ILC3s. We show that 1,25D represses the IL-23R pathway and consequently the IL-23-regulated production of IL-22, IL-17F, and GM-CSF. Simultaneously, 1,25D upregulates key components of the IL-1b pathway and skews ILC3 cytokine secretion toward a more innate cell profile, including production of IL-6, IL-8, and macrophage inflammatory protein (MIP) 1a/ b. Our study reveals 1,25D as potent modulator of ILC3 function, with important implications for diseases in which ILC3s are involved and 1,25D has beneficial effects, such as IBD and psoriasis. 
Cell isolation from human tonsil and gut
Human tonsillar ILC3s and natural killer (NK) cells were isolated by means of flow cytometric sorting, as previously described.
2 Gut single-cell suspensions and sorted ILC3s were derived from gut biopsy specimens of adults with IBD in remission (see Table E1 in this article's Online Repository at www.jacionline.org).
In vitro stimulation, intracellular staining, and analysis of proliferation Sort-purified tonsillar and gut ILCs and gut single-cell suspensions were cultured with 100 nmol/L 1,25D or 25-hydroxy vitamin D3 (25D) or vehicle, IL-23 plus IL-1b (50 ng/mL), and IL-23 plus IL-1b plus 1,25D for 24 or 72 hours. When indicated, cells were additionally stimulated with 25 ng/mL phorbol 12-myristate 13-acetate (PMA) plus 500 nmol/L ionomycin for 6 hours. Tonsillar NK cells were stimulated with IL-12 plus IL-18 (50 ng/mL). After performing the different staining protocols, cells were immediately acquired on a LSR Fortessa flow cytometer (BD Biosciences, San Jose, Calif).
ELISA and multiplex immunoassay
Cell supernatants were analyzed by using the Human IL-22 and IL-17F DuoSet ELISA (R&D Systems, Minneapolis, Minn) and Bio-Plex Pro Human Cytokine 27-plex Kit (Bio-Rad Laboratories, Hercules, Calif).
RNA isolation and microarray gene expression analysis
Total RNA of ILC3s was isolated by using the RNeasy Micro Kit (Qiagen, Hilden, Germany). Microarray analysis was performed by using the Human Transcriptome Array 2.0. Data correction and heat map analysis were performed with R software. 40, 41 25D detection in plasma samples of patients with IBD Peripheral blood of patients with IBD (see Table E2 in this article's Online Repository at www.jacionline.org) was collected at the Gastromedical Center, Karolinska Institutet. 25D in plasma samples was analyzed by using a chemiluminescence immunoassay.
Statistical analyses
Data were analyzed by using the Wilcoxon matched-pairs signed rank test or 1-way ANOVA and the Tukey multiple comparisons test with GraphPad Prism 6 Software (GraphPad Software, La Jolla, Calif).
RESULTS

Activated ILC3s upregulate VDR, and 1,25D induces broad transcriptional changes
To assess functional responses of ILC3s to 1,25D, we sort purified bulk ILC3s containing NKp44 2 and NKp44 1 ILC3s from tonsillar tissue. The tonsils are mucosa-associated lymphoid tissue containing all ILC populations reported thus far.
2 Therefore we performed our initial experiments with tonsillar tissue to later confirm key findings in intestinal tissue.
ILC3s were sorted by means of flow cytometry as lineagenegative cells lacking expression of B-cell, T-cell, myeloid cell, and mast cell markers and were defined as CD45
CRTH2
2 lymphocytes (Fig 1, A) . First, we wanted to assess, in an unbiased manner, the effects of vitamin D on human ILC3s by using the active form 1,25D (100 nmol/L). For this purpose, we performed transcriptomic analysis of bulk ILC3s after 24 hours of stimulation with vehicle (0.0002% EtOH), 1,25D, IL-23 plus IL-1b (each 50 ng/mL), or IL-23 plus IL-1b plus 1,25D. We analyzed differentially regulated genes among all treatment groups (Fig 1, B) . Whereas 1,25D alone induced modest transcriptional changes, IL-23 plus IL-1b stimulation of ILC3s (referred to as activated ILC3s hereafter) led to significant regulation of 321 genes, with VDR being the most significantly upregulated transcripts (Fig 1, C and D) . These data indicated that IL-23 plus IL-1b activation rendered ILC3s responsive to 1,25D (Fig 1, C) . We used gene ontology enrichment analysis to assess overall changes in transcriptional patterns, which revealed negative regulation of protein phosphorylation, cytokine-mediated signaling pathways, and cytokine production by 1,25D in activated ILC3s (see Fig E1 in this article's Online Repository at www.jacionline.org). In parallel, 1,25D upregulated genes related to small-molecule metabolic processes, innate immune and stress response, and single-organism metabolic processes (see Fig E1) .
On in-depth evaluation of the transcriptional changes, we observed that treatment of activated ILC3s with 1,25D triggered significant regulation of several VDR target genes, including CYP24A1, a 24-hydroxylase enzyme degrading the active 1,25D compound. Additionally, CAMP (LL-37, antimicrobial peptide) 42 and MN1 (meningioma-1, a coactivator of VDR-mediated transcription) 43 were significantly upregulated (Fig 1, C and D) . Furthermore, 1,25D upregulated the VDR target genes interferon regulatory factor 8 (IRF8) and SERPINB1, factors known as negative modulators of T H 17 cells. 44, 45 Notably, 1,25D skewed the gene expression profile of activated ILC3s toward that of tissueresident cells, as demonstrated by modulation of genes involved in immune cell homing and adhesion, as well as in regulation of actin polymerization and motility (see Fig E2, A, in this article's Online Repository at www.jacionline.org). Additionally, numerous metabolism-related genes were upregulated by 1,25D in activated ILC3s, with particular enrichment of lipid metabolism genes (see Fig E2, B) .
These data provide compelling evidence that activated ILC3s respond intensively to 1,25D, with transcriptional changes of a wide range of known VDR target genes and an enhanced transcriptional program aimed at tissue residency.
1,25D does not affect differentiation, viability, or proliferation of activated ILC3s
An important function of 1,25D is to modulate the differentiation and proliferation of immune cells. 46 Thus we investigated whether 1,25D could influence ILC3 differentiation by affecting NKp44 expression, which is a marker of IL-22-producing ILC3s in human subjects.
1 Notably, the IL-23 plus IL-1b-induced increase in ILC3 NKp44 expression was not affected by 1,25D (Fig 2, A and B) . Additionally, 1,25D had no effect on the expression of other ILC3 markers, such as CD127, CD117, and CD161 (data not shown).
On the transcriptional level, 1,25D modulated the expression of several genes involved in cell survival and proliferation, as well as proapoptotic and antiapoptotic genes (see Fig E2, C) . Thus we J ALLERGY CLIN IMMUNOL VOLUME 141, NUMBER 1 investigated whether 1,25D could influence ILC3 viability and proliferation beyond inducing transcriptional changes. Sortpurified ILC3s were incubated with vehicle, 1,25D, IL-23 plus IL-1b, or IL-23 plus IL-1b plus 1,25D for 72 hours. Importantly, 1,25D did not affect ILC3 viability (Fig 2, C) . Additionally, the IL-23 plus IL-1b-triggered proliferation of NKp44 1 and NKp44 2 ILC3s was also not markedly influenced by 1,25D (Fig 2, D and E) .
These data clearly suggest that the effects of 1,25D on activated ILC3s do not include and are not mediated by alterations in viability, proliferation, or differentiation status of ILC3s.
1,25D downregulates the IL-23R regulatory pathway in activated tonsillar ILC3s
Transcriptomic analysis of highly purified tonsillar ILC3s revealed that IL-23 plus IL-1b treatment caused differential hours. D, Relative signal intensity 6 SD of VDR and VDR target genes transcripts (n 5 3). *P < .05, **P < .01, ***P < .005, and ****P < .001.
regulation of several genes compared with vehicle treatment. We confirmed numerous genes, including IL22, CSF2, IL17F, IL26, and IFNG, that had been previously shown to be expressed by activated tonsillar ILC3 (see Fig E2, D) . 4 Coincubation of activated ILC3s with 1,25D resulted in profound transcriptional changes affecting crucial ILC3 functions, which is in line with the observed upregulation of VDR in activated ILC3s (Fig 3,  A) . Most importantly, the transcript of IL23R, the main driver of ILC3 cellular activity, was significantly downregulated by 1,25D. Consequently, transcripts downstream of IL-23R, including RORC, IL22, IL17F, IL26, IFNG, and CSF2, were also suppressed. We did not observe significant regulation of AHR gene expression at 24 hours of stimulation. We confirmed the 1,25D-induced downregulation of IL23R on NKp44 1 and NKp44 2 ILC3s by analyzing the IL-23R cell-surface protein using flow cytometry (Fig 3, B and C) .
Because 1,25D clearly downregulated the IL-23R and cytokine transcripts associated with this pathway, we next assessed the IL-23R-associated and ILC3-specific transcription factors AhR and RORgt. IL-23 plus IL-1b treatment led to upregulated protein expression of these transcription factors, which was reduced by 1,25D (Fig 3, D and E) . Interestingly, in response to 1,25D, NKp44 1 ILC3s showed more prominent downregulation of AhR and RORgt expression compared with that in NKp44 2 ILC3s (Fig 3, D and E) .
These results provide the first evidence that 1,25D acts as a silencer of the IL-23R regulatory pathway in human ILC3s.
1,25D selectively prevents ILC3 responses to IL-23 cytokine stimulation
We next sought to dissect the relative contribution of the ILC3-activating cytokines IL-23 and IL-1b in mediating the responsiveness to and effects of 1,25D.
Sort-purified ILC3s secreted IL-22 and IL-17F upon IL-23 stimulation, and secretion was synergistically enhanced by combined IL-23 plus IL-1b stimulation (Fig 4, A, and see Fig E3, A and B, in this article's Online Repository at www.jacionline. org). ILC3-derived GM-CSF can also contribute to the pathogenesis of gut inflammation. 5, 47, 48 However, in contrast to IL-22, GM-CSF production was dependent on IL-1b stimulation, which was further enhanced by IL-23 after 24 hours of stimulation (see Fig E3, C) . After 72 hours, GM-CSF production might have reached its maximum on IL-1b stimulation and was not further inducible by IL-23 (Fig 4, B) . In line with the 1,25D-induced downregulation of the IL-23R pathway, 1,25D only inhibited . E, Normalized geometric MFI of AhR and RORgt. Dot plots show means 6 SDs (n 5 6). *P < .05, **P < .01, ***P < .005, and ****P < .001.
the IL-23-stimulated or synergistically costimulated secretion of IL-22, IL-17F, and GM-CSF but did not modulate IL-1b-mediated effects (Fig 4, A and B) . Similarly, 1,25D reduced the IL-23-dependent intracellular expression of IL-22 and GM-CSF in NKp44 1 ILC3s (Fig 4, C-F) but not IL-1b-dependent GM-CSF expression (Fig 4, C-F) . Interestingly, although activated ILC3s secreted IL-17F after 24 and 72 hours, which was inhibited by 1,25D (Fig 4, A, and see Fig E3, B) , intracellular detection of IL-17F revealed no such effects (Fig 4, E and F) . In contrast to IL-17F, activated ILC3s secreted small amounts of IL-17A, which was not modified by 1,25D (see Fig E4, A, in this article's Online Repository at www.jacionline.org). IL-17A was also not detectable intracellularly in the ILC3 subsets (data not shown). These data are supported by the notion that in our microarray analysis IL17A transcripts were not upregulated in activated ILC3s. Furthermore, low amounts of secreted and intracellular IFN-g were detected when ILC3s were stimulated with IL-23 plus IL1b, which was inhibited by 1,25D (see Fig E4, B-D) . Notably, (Fig 4, A) and GM-CSF (Fig 4, B) release of sorted tonsillar ILC3s after 72 hours was analyzed by means of ELISA. Mean 1 SD concentration is shown (n 5 3). C, Intracellular IL-22 and GM-CSF expression of NKp44 . *P < .05, **P < .01, ***P < .005, and ****P < .001. ) . B, Gating strategy for identifying ILC3 and T-cell subsets in noninflamed gut biopsy cell suspensions. C and E, Intracellular expression of IL-22 and GM-CSF was analyzed on gated NKp44 1 ILC3s (Fig 6, C) and CD4 1 T cells (Fig 6, E) after 24 hours. In some cases cell suspensions were incubated in the presence of PMA (25 ng/mL) plus ionomycin (500 nmol/L) in the last 6 hours (n 5 7). D, Individual percentages of positive cells are shown (n 5 7). F, Individual percentages of positive cells are shown (n 5 7). *P < .05, **P < .01, ***P < .005, and ****P < .001.
J ALLERGY CLIN IMMUNOL VOLUME 141, NUMBER 1 tonsillar NK cell IFN-g and GM-CSF production, stimulated by IL-12 plus IL-18, was completely unaffected by 1,25D (see Fig  E5 in this article's Online Repository at www.jacionline.org). The active form of vitamin D, 1,25D, is synthetized from the inactive proform 25-hydroxyvitamin D3 (25D) by the enzyme 25D-1-a-hydroxylase (CYP27B1), which we showed was expressed in ILC3s (Fig 1, C) . 36 Strikingly, 25D mimicked the effects of 1,25D on stimulated ILC3s in reducing IL-22 and GM-CSF cytokine secretion (see Fig E6, A and B, in this article's Online Repository at www.jacionline.org) and also prevented upregulation of RORgt and AhR in both ILC3 subsets (see Fig E6, C  and D) . The latter findings suggest that ILC3s can convert 25D to 1,25D intrinsically.
Together, these data demonstrate that 1,25D and the inactive proform 25D limit responsiveness of ILC3s to IL-23, as evidenced by reduced IL-22, IL-17F, and GM-CSF production.
1,25D upregulates IL-1b-inducible genes and cytokines in activated tonsillar ILC3s
In addition to the transcriptional changes in genes involved in VDR and IL-23 responses, 1,25D triggered upregulation of a distinct set of genes involved in the IL-1b signaling pathway (Fig  5, A) . IL-1b mediates its effects through IL-1R1, and its signal transduction involves the adaptor molecule IL-1 receptoractivated protein kinase 2 (IRAK2), the downstream mitogenactivated protein kinases, c-Jun N-terminal kinases, and, subsequently, NF-kB and members of the activating protein 1 transcription factor family. 49 Canonical IL-1b target genes are those encoding IL-6, IL-8, MIP-1a/b, and COX-2. The combination of IL-23 plus IL-1b plus 1,25D stimulation of ILC3s led to upregulation of IRAK2, JUN, and FOSL2, which encode proteins crucially involved in the IL-1b signaling pathway (Fig 5, B) . However, expression of IL-1R1 protein was not influenced by was analyzed by using a multiplex ELISA after 72 hours. Bars represent means 6 SDs (n 5 3). *P < .05 and **P < .01.
1,25D treatment of activated ILC3s (see Fig E7 in this article's
Online Repository at www.jacionline.org). Notably, we also observed highly significant upregulation of IL-1b-inducible cytokine/chemokine genes, such as IL6, IL8, CCL3, CCL4, and CSF1, on VDR engagement in activated ILC3s (Fig 5, A) .
In line with the transcriptional changes, we confirmed that secretion of IL-6, IL-8, and MIP-1a/b was induced by 1,25D treatment in activated ILC3s (Fig 5, C) . Interestingly, the mechanism behind the enhanced production of IL-6 was different from that of the latter cytokines. IL-6 was the only cytokine induced by the combination of 1,25D plus IL-1b (ie, in the absence of IL-23; Fig 5, C) . Notably, IL-23 plus 1,25D stimulation did not enhance secretion of any of these IL-1b-inducible cytokines/chemokines. To further validate our findings and assess the cellular sources of IL-6 within the ILC3 population, we performed intracellular IL-6 detection (Fig 5, D and E) . Both ILC3 subsets expressed IL-6 after incubation with IL-23 plus IL-1b plus 1,25D-stimulation, but it was particularly pronounced in NKp44 1 ILC3s (up to 10%; Fig  5, D) . Compared with IL-23 plus IL-1b stimulation, 1,25D shifted NKp44 1 ILC3 cytokine production to reduce IL-22 but acquire IL-6 expression (Fig 5, D) . Interestingly, approximately 15% of IL-22-expressing NKp44 1 ILC3s coexpressed IL-6. These data show that in addition to downregulation of the IL-23R regulatory pathway, 1,25D simultaneously turns on genes that belong to the IL-1b signaling cascade, with a consequent induction of IL-1b-inducible cytokines, such as IL-6, in activated ILC3s.
1,25D selectively inhibits IL-22 and GM-CSF production of activated intestinal NKp44
1 ILC3s but not in CD4
1 T cells
ILC3s are the most abundant intestinal ILC population. The healthy human gut mucosa is dominated by the NKp44 1 ILC3 subset. [3] [4] [5] 20 We isolated single-cell suspensions from biopsy specimens of noninflamed ileum or colons of adults with IBD in remission (see Table E1 ). To mimic inflammation, we stimulated total intestinal cell suspensions with IL-23 plus IL-1b, which significantly increased IL-22 secretion (Fig 6, A) . As demonstrated for tonsillar ILC3s, IL-22 production was markedly reduced by 1,25D (Fig 6, A) . Additionally, we detected low levels of secreted IL-17A and IL-17F from activated intestinal cell suspensions, which were slightly but not significantly decreased by 1,25D (Fig 6, A) .
We next set out to uncover which cellular source of IL-22 in the intestine is affected by 1,25D. To that end, NKp44
1 ILC3s and CD4 1 T cells were analyzed for intracellular expression of IL-22 and also GM-CSF (Fig 6, B) 
CD4
1 lymphocytes. Intestinal NKp44
1 ILC3s responded to IL-23 plus IL-1b stimulation, with, on average, 15% of the cells producing IL-22, although 1,25D coincubation reduced this to 3.5% (Fig 6, C and D) . We detected only weak GM-CSF expression on activation, which was clearly decreased by 1,25D. Notably, we were not able to detect GM-CSF in the intestinal cell suspension supernatants (data not shown). On augmentation of cytokine production by PMA plus ionomycin, approximately 25% of NKp44 1 ILC3s became IL-22 1 cells after cytokine activation, and 1,25D clearly disabled the IL-22 production (Fig 6, C and D) .
In line with our findings in tonsillar ILC3s, 1,25D reduced IL-22 but did not affect GM-CSF production in PMA plus ionomycin-exposed intestinal NKp44
1 ILC3s (Fig 6, C 
org). Additionally, NKp44
2 ILC3s slightly increased IL-22 expression on IL-23 plus IL-1b stimulation, which was inhibited by 1,25D (see Fig E9, A and B, in this article's Online Repository at www.jacionline.org). In contrast, CD4
1 T cells did not respond to IL-23 plus IL-1b stimulation with increased IL-22 or GM-CSF expression (Fig 6, E) . However, on PMA plus ionomycin exposure, on average, 7% of CD4 1 T cells were IL-22 1 and 30% were GM-CSF 1 (Fig 6, E and F) . Strikingly, 1,25D did not influence IL-22 and GM-CSF production in CD4 1 T cells. CD8
1 T cells only scarcely displayed IL-22 expression on activation, and it was not affected by 1,25D (see Fig E9, C and D) .
These data clearly indicate that 1,25D exclusively controls IL-22 and GM-CSF production by intestinal NKp44 1 ILC3s but not that of CD4
1 T cells stimulated with IL-23 plus IL-1b.
1,25D reprograms sorted intestinal ILC3s by suppressing IL-22 and GM-CSF production while inducing IL-6 secretion
ILC3s were sort purified from noninflamed ileum biopsy samples of patients with IBD in remission by using the same gating strategy as for tonsillar ILC3 sorting (Fig 1, A) . Because of low ILC3 sorting yield from human gut biopsy specimens, in some experiments ILC3s were pooled from 2 patients (see Table E1 ). After 72 hours of culture, gut ILC3s retained their phenotype, with high surface expression of CD117 and CD161 (Fig 7, A) . On average, activated gut ILC3s showed 10% higher frequency of NKp44 1 ILC3s compared with vehicle, and similar to tonsil-derived ILC3, the composition of ILC3 subsets was not affected by 1,25D (Fig 7, A and B) . With regard to cytokine secretion, we found augmented IL-22, GM-CSF, and IFN-g levels on activation, which were almost completely prevented by 1,25D (Fig 7, C) . Paralleling the findings with tonsillar ILC3s, activated gut ILC3s also displayed induced IL-6 production on 1,25D treatment (Fig 7, C) . These data demonstrate that 1,25D reprograms gut ILC3 cytokine production, which provides important pathophysiologic insights. These experiments highlight that ILC3s are functionally very plastic lymphocytes, and thus 1,25D is able to suppress IL-23-driven IL-22 and IL-17F expression and enhance IL-1b-triggered production of IL-6, IL-8, and MIP-1a/b (displayed in the Graphical Abstract).
Patients with IBD and active inflammation are vitamin D deficient
Patients with IBD have been shown to have lower plasma levels of 25D than healthy control subjects, but this association is not clear in all cohorts. 50 Therefore we determined 25D plasma levels in a cohort of patients with IBD collected at our gastromedical center (Fig 8 and see Tables E1 and E2 ). On average, the 25D plasma levels of patients with active inflammation were less than 50 nmol/L, which is defined as insufficient according to the Institute of Medicine guidelines. 51 In contrast, patients with Lynch syndrome and IBD in remission exhibited higher 25D levels. These observations, along with our detailed mechanistic description of how 1,25D reprograms intestinal ILC3s, strongly argue for the importance of vitamin D supplementation studies of patients with IBD.
DISCUSSION
The IL-23R pathway is one of the most extensively studied risk pathways for IBD, and variants of the IL23R gene might be protective or cause an inappropriate immune response to the commensal flora of the gut. 52 Downstream genes of the IL-23R pathway, including IL22, IL17A, and IL17F, have also been identified as IBD risk loci and found to be overexpressed in colonic mucosa in patients with CD and those with ulcerative colitis. 52, 53 Indeed, targeting IL-23/IL-12 with ustekinumab is beneficial for patients with CD who do not respond to anti-TNF therapy. [25] [26] [27] ILC3s and T H 17/22 cells share similar transcriptional programs and cytokine production profiles in response to IL-23. 53 Strikingly, the IL-23-driven IL-22 secretion of ILC3s can be protective in intestinal homeostasis and inflammation, [5] [6] [7] [8] but it can also exert deleterious effects in gut inflammation and tumorigenesis. [9] [10] [11] [12] [13] [14] Similarly, the IL-23-induced production of IL-17 contributes to the development of colitis, 15, 20 whereas IL-23-independent IL-17 production was recently shown to promote intestinal barrier function. 54 Consequently, therapeutic targeting of IL-17 was ineffective, even leading to adverse outcomes in patients with CD. 16 Hence IL-17 and IL-22 can have both tissue-protective and deleterious effects in the intestine. Nevertheless, blocking the IL-23/ 12 pathway seems to have only beneficial effects in patients with IBD.
Vitamin D deficiency is a known risk factor for IBD, 55 and a recent 5-year longitudinal study revealed that normal 25D levels and vitamin D supplementation reduced markers of disease activity in patients with IBD. 29 In a small cohort of patients with IBD, we demonstrated that patients with active inflammation are vitamin D deficient, whereas patients in remission have normalized 25D levels. However, high-quality randomized placebocontrolled trials are required to establish vitamin D as a therapeutic option for IBD. We demonstrated here that IL-23 plus IL-1b-activated ILC3s upregulate VDR expression. In response to the active form of vitamin D (1,25D) , ILC3s downregulated IL-23R and consequently the IL-23R pathway (AhR, RORgt, IL-22, IL-17F, and GM-CSF), which could have dramatic consequences for intestinal health because previous reports identify IL-23 as a local driver of intestinal inflammation through inducing production of IL-22, IL-17, and GM-CSF. 15, 20, 47, 56 It is noteworthy that 1,25D only inhibited IL-23R-dependent secretion of GM-CSF, whereas IL-1b-induced GM-CSF production was maintained, possibly providing intestinal tolerance, as reported by others. 48 Therefore our data suggest that vitamin D supplementation of deficient patients with IBD might provide a promising strategy to diminish mucosal inflammation similar to what is observed in patients treated with ustekinumab. [25] [26] [27] Vitamin D was previously shown to inhibit T H 17 differentiation and cytokine production through inhibiting nuclear factor for activated T cells (NFAT). 37 In addition to VDR, the transcription factor IRF8 and the SERPINB1 gene can also act as silencers of T H 17 function. 44, 45 Notably, both IRF8 and SERPINB1 are VDR target genes 57, 58 and were significantly upregulated by 1,25D in activated ILC3s in the microarray analysis, suggesting involvement of multiple factors in downregulating the IL-23R pathway in 1,25D-treated activated ILC3s.
Apart from IL-23R, patients with CD commonly display polymorphisms in genes related to pathogen recognition and autophagy relevant to bacterial killing in macrophages (NOD2/ CARD15, IRGM, and ATG16L1).
52 Accordingly, CD is associated with a defective acute inflammatory response failing to fight the accumulated bacteria, which then persist and evoke a secondary chronic inflammation. 59 At the onset of IBD, there is an inappropriate innate response of macrophages, the major source of IL-6 and IL-8, to the accumulated bacteria. This impaired defense line results in insufficient infiltration of neutrophils to the site of infection. 59 Notably, 1,25D was shown to enhance bacterial killing of macrophages isolated from patients with CD. 60 In addition, 1,25D induced production of IL-1b, IL-6, and IL-8, but not GM-CSF, in Mycobacterium tuberculosis-infected macrophages, which was essential in host defense. 61 ILC3s, as intestinal mucosa-resident immune cells, are crucially involved in acute inflammation, mainly through secreting IL-22. 62 Although vitamin D has shown protective effects in patients with IBD, it can obviously promote production of innate-like cytokines. Yet the role of ILC3s in producing such cytokines is poorly characterized. We revealed that 1,25D induced upregulation of genes linked to IL-1b signaling (IRAK2, FOSL2, JUN, and PRKCB) in activated tonsillar ILC3s without affecting IL-1R1 expression. Consequently, the IL-1b-inducible cytokines IL-6, IL-8, and MIP-1a/b were secreted by activated ILC3s in response to 1,25D. Intestinal ILC3s also shifted the cytokine production profile from IL-22 and GM-CSF to IL-6. In contrast to IL-6, IL-8, and MIP-1a/b, the IL-1b-induced GM-CSF production was not affected by 1,25D, which suggests a distinct regulation of this cytokine, as previously shown in macrophages. 61, 63 Hence our findings suggest that 1,25D enables ILC3s to acquire an innate-like cytokine expression profile. Thus ILC3s might essentially contribute to infiltration of phagocytic monocytes and neutrophils to the site of bacterial infiltration at the onset of IBD. This thus far unappreciated involvement of ILC3s in regulating immune cell trafficking during acute inflammation might further enhance the robustness of the intestinal immune system. The role of IL-6 in inflammation is very complex because of its soluble and membrane-bound receptors. 64 Interestingly, IL-6, similar to IL-22, activates signal transducer and activator of transcription 3 (Stat3) phosphorylation in intestinal epithelial cells, which triggers wound healing and mucosal repair. [65] [66] [67] Consistently, anti-IL-6R therapy, although displaying beneficial effects for patients with CD, did not improve mucosal healing. 68 This notion supports that the 1,25D-induced modulation of ILC3 function might be of relevance in intestinal inflammation.
Notably, the inactive vitamin D proform 25D mimicked 1,25D in modulating the ILC3 cytokine production profile, indicating that ILC3s are able to synthesize 1,25D. Of note, 1,25D did not modulate activated tonsil NK cells. Intestinal CD4
1 T cells only produced IL-22 and GM-CSF after combined stimulation of IL-23 plus IL-1b and PMA plus ionomycin. However, 1,25D did not affect CD4
1 T-cell cytokine production, which can be explained by previous reports showing that VDR expression in T cells is T-cell receptor activation dependent. 38 Thus a-CD3/CD28 stimulation would be required for making T cells responsive to 1,25D. Nevertheless, our results suggest that 1,25D exclusively suppresses the innate responsiveness of ILCs and not that of T cells.
Taken together, our data clearly demonstrate that activated human ILC3s are rendered responsive to vitamin D, which causes downregulation of the IL-23R pathway and simultaneously shifts ILC3 cytokine production to innate-type cytokines, including IL-6, IL-8, and MIPs. We show evidence that patients with IBD are vitamin D deficient, and hence targeting VDR in patients with IBD is highly relevant and would directly affect ILC3 functions crucial in orchestrating innate immune responses.
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